(PRWEB) May 09, 2013
For the first time in 55 years, spending on medications in the United States has dropped, in part because of patent expirations for popular drugs such as Lipitor.* The Rottenstein Law Group LLP, a Lipitor law firm, offers its opinion on what this means for those who seek to file Lipitor lawsuits because they suffered from Lipitor-induced diabetes.
Pfizer lost patent protection for Lipitor in 2011, which led to other manufacturers’ selling cheaper generic versions of the drug. Given the great number of Lipitor users, that switch to generic plays a large role in reduced spending, according to a May 9 Reuters report.
But despite the availability of inexpensive Lipitor, Rottenstein Law Group LLP principal Rochelle Rottenstein notes that studies have been released that indicate there could be some serious risks that go along with using Lipitor. She cites a January 2012 study in JAMA: Internal Medicine that indicated there is a potential link between statins and a Type 2 diabetes risk in women.**
“Even though generics present a cheaper alternative, there are still some people buying name-brand Lipitor,” Rottenstein said. “Those people are at risk of suffering the alleged side effects that could make them eligible to file a lawsuit.”
Plaintiffs across the United States have filed lawsuits, many of which are under consideration for consolidation into a multidistrict litigation for efficient pretrial proceedings (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (JPML)).
The Rottenstein Law Group LLP’s Lipitor Lawsuit Information Center offers a comprehensive look at Lipitor side effects and how to file a Lipitor lawsuit.
Copyright©2012 Vocus, Inc.
All rights reserved